Regeneron Pharmaceuticals (REGN) FY2025 10-K Annual Report
Regeneron Pharmaceuticals (REGN) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 4, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Regeneron Pharmaceuticals FY2025 10-K Analysis
Business Overview
- • Core business model: Development, manufacturing, and commercialization of innovative biologic drugs and drug-delivery devices with regulatory approval focus
- • New emphasis on expanding internal manufacturing capacity and establishing fill/finish capabilities amid production constraints and pandemic-related impacts
- • Strategic reliance increased on collaborators and contract manufacturers for bulk production and complex device supply chain management
- • Manufacturing capacity limited to facilities in Rensselaer, NY and Limerick, Ireland; investing in expansion and new fill/finish facility undergoing process validation
- • Noteworthy risk: Loss of U.S. market exclusivity for EYLEA as biosimilars launched May 2024, impacting patent protection and revenue outlook
Management Discussion & Analysis
- • No revenue or profitability figures provided in the excerpt
- • No segment performance details disclosed
- • Investment portfolio equity securities decreased to $515.8M (Dec 31, 2025) from $1.307B (Dec 31, 2024)
- • Foreign exchange risk growing due to international sales and operations; foreign currency hedging strategies considered
- • No cash flow, capital allocation, or forward-looking guidance included
Risk Factors
- • Lease financing $720M matures March 2027, full payment due unless extended with lender consent
- • Exposure to SOFR-based variable interest rate plus margin tied to debt rating and leverage ratio
- • Liabilities for unrecognized tax benefits $1.578B as of December 31, 2025, with high uncertainty in settlement timing
- • Ongoing R&D and commercialization costs depend on trial outcomes, regulatory approvals, and market potential
- • Contingent payments from collaboration agreements include milestone and royalty payments with unpredictable timing
Regeneron Pharmaceuticals FY2025 Key Financial MetricsXBRL
Revenue
$14.3B
▲ +1.0% YoY
Net Income
$4.5B
▲ +2.1% YoY
Operating Margin
24.9%
▼ -315bp YoY
Net Margin
31.4%
▲ +34bp YoY
ROE
14.4%
▼ -62bp YoY
Total Assets
$40.6B
▲ +7.4% YoY
EPS (Diluted)
$41.48
▲ +8.2% YoY
Operating Cash Flow
$5.0B
▲ +12.6% YoY
Source: XBRL data from Regeneron Pharmaceuticals FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Regeneron Pharmaceuticals
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.